A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Gemcitabine (Primary) ; Ivospemin (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms ASPIRE
- Sponsors Panbela Therapeutics
- 24 Jun 2024 According to a Panbela Therapeutics media release, The DSMB recommended study continuation without modification, marking the third consecutive positive safety review.
- 24 Jun 2024 According to a Panbela Therapeutics media release, the interim survival analysis will be available as early as the first quarter of 2025
- 15 May 2024 According to a Panbela Therapeutics media release, Research and development expenses were approximately $5.5 million, compared to $3.5 million in the same period last year. This increase is primarily due to significant growth in the number of active sites and enrollment in project ASPIRE.